RedHill Secures Global Rights to Rebyota and U.S. Rights to Clenpiq in $12M Upfront Deal
RDHL sits 61% above its 52-week low of $0.57 on elevated volume (56× avg).
Summary
RedHill acquired exclusive global commercialization rights to Rebyota and U.S. rights to Clenpiq from Ferring for $12 million upfront, funded by the Talicia divestiture. The products generated ~$37.5M in 2025 U.S. net sales.
Key Events · M&A and Partnerships · RDHL
-
License Agreement with Ferring
RedHill acquired exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq for a $12 million upfront payment, tiered royalties of 5-20% on net sales, and potential capped milestones.
-
Revenue Base of $37.5M
The two products generated approximately $37.5 million in 2025 U.S. net sales — Rebyota at $16.9M and Clenpiq at $20.6M — providing RedHill with immediate commercial revenue.
-
Fully Funded by Talicia Divestiture
The $12 million upfront payment is fully covered by the $18 million cash received from the Talicia sale to Apotex, leaving RedHill with additional liquidity and no new dilution.
-
13-Year Term with Renewals
The agreement has an initial 13-year term with automatic two-year renewals, plus minimum annual purchase commitments for Rebyota during 2027-2029.
Analysis · RDHL · Life Sciences
This deal fundamentally reshapes RedHill's commercial GI business by bringing in exclusive rights to two FDA-approved, revenue-generating products from Ferring. The $12 million upfront payment is fully covered by the recently completed $18 million Talicia divestiture, so no new dilution is required. The acquired products generated approximately $37.5 million in 2025 U.S. net sales — more than six times RedHill's current market cap — and are expected to contribute positive cash flow immediately. It marks a major strategic repositioning that shifts RedHill from a cash-strapped micro-cap with going-concern warnings toward a self-sustaining commercial operation.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.5% of the 522 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDHL was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.57 to $2.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.